182 related articles for article (PubMed ID: 33892482)
1. Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option.
Ferrara B; Belbekhouche S; Habert D; Houppe C; Vallée B; Bourgoin-Voillard S; Cohen JL; Cascone I; Courty J
Nanotechnology; 2021 May; 32(32):. PubMed ID: 33892482
[TBL] [Abstract][Full Text] [Related]
2. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia.
Mongelard F; Bouvet P
Curr Opin Mol Ther; 2010 Feb; 12(1):107-14. PubMed ID: 20140822
[TBL] [Abstract][Full Text] [Related]
3. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Bates PJ; Reyes-Reyes EM; Malik MT; Murphy EM; O'Toole MG; Trent JO
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1414-1428. PubMed ID: 28007579
[TBL] [Abstract][Full Text] [Related]
4. Targeting nucleolin to obstruct vasculature feeding with an intelligent DNA nanorobot.
Li H; Liu J; Gu H
J Cell Mol Med; 2019 Mar; 23(3):2248-2250. PubMed ID: 30592140
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic applications of AS1411 aptamer, an update review.
Yazdian-Robati R; Bayat P; Oroojalian F; Zargari M; Ramezani M; Taghdisi SM; Abnous K
Int J Biol Macromol; 2020 Jul; 155():1420-1431. PubMed ID: 31734366
[TBL] [Abstract][Full Text] [Related]
6. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
7. A dual-targeting DNA tetrahedron nanocarrier for breast cancer cell imaging and drug delivery.
Liu X; Wu L; Wang L; Jiang W
Talanta; 2018 Mar; 179():356-363. PubMed ID: 29310244
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
Rosenberg JE; Bambury RM; Van Allen EM; Drabkin HA; Lara PN; Harzstark AL; Wagle N; Figlin RA; Smith GW; Garraway LA; Choueiri T; Erlandsson F; Laber DA
Invest New Drugs; 2014 Feb; 32(1):178-87. PubMed ID: 24242861
[TBL] [Abstract][Full Text] [Related]
9. Nucleolin mediates the antiangiogenesis effect of the pseudopeptide N6L.
Birmpas C; Briand JP; Courty J; Katsoris P
BMC Cell Biol; 2012 Nov; 13():32. PubMed ID: 23146273
[TBL] [Abstract][Full Text] [Related]
10. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.
Reyes-Reyes EM; Teng Y; Bates PJ
Cancer Res; 2010 Nov; 70(21):8617-29. PubMed ID: 20861190
[TBL] [Abstract][Full Text] [Related]
11. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ
Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047
[TBL] [Abstract][Full Text] [Related]
12. Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells.
Mosafer J; Teymouri M; Abnous K; Tafaghodi M; Ramezani M
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():123-133. PubMed ID: 28024568
[TBL] [Abstract][Full Text] [Related]
13. Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type.
Krust B; El Khoury D; Nondier I; Soundaramourty C; Hovanessian AG
BMC Cancer; 2011 Aug; 11():333. PubMed ID: 21812966
[TBL] [Abstract][Full Text] [Related]
14. Cell surface nucleolin as a target for anti-cancer therapies.
Koutsioumpa M; Papadimitriou E
Recent Pat Anticancer Drug Discov; 2014 May; 9(2):137-52. PubMed ID: 24251811
[TBL] [Abstract][Full Text] [Related]
15. Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.
Carvalho J; Paiva A; Cabral Campello MP; Paulo A; Mergny JL; Salgado GF; Queiroz JA; Cruz C
Sci Rep; 2019 May; 9(1):7945. PubMed ID: 31138870
[TBL] [Abstract][Full Text] [Related]
16. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.
Bates PJ; Laber DA; Miller DM; Thomas SD; Trent JO
Exp Mol Pathol; 2009 Jun; 86(3):151-64. PubMed ID: 19454272
[TBL] [Abstract][Full Text] [Related]
17. Targeting nucleolin for better survival in diffuse large B-cell lymphoma.
Jain N; Zhu H; Khashab T; Ye Q; George B; Mathur R; Singh RK; Berkova Z; Wise JF; Braun FK; Wang X; Patel K; Xu-Monette ZY; Courty J; Young KH; Sehgal L; Samaniego F
Leukemia; 2018 Mar; 32(3):663-674. PubMed ID: 28690315
[TBL] [Abstract][Full Text] [Related]
18. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery.
Wu J; Song C; Jiang C; Shen X; Qiao Q; Hu Y
Mol Pharm; 2013 Oct; 10(10):3555-63. PubMed ID: 23679916
[TBL] [Abstract][Full Text] [Related]
19. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
Soundararajan S; Chen W; Spicer EK; Courtenay-Luck N; Fernandes DJ
Cancer Res; 2008 Apr; 68(7):2358-65. PubMed ID: 18381443
[TBL] [Abstract][Full Text] [Related]
20. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells.
Zhou W; Zhou Y; Wu J; Liu Z; Zhao H; Liu J; Ding J
J Drug Target; 2014 Jan; 22(1):57-66. PubMed ID: 24156476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
